Join
Live feed
·
PRReleasevia Quantisnow
Evommune Inc. logo

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

ByQuantisnow·Wall Street's wire, on your screen.
EVMN· Evommune Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EVMN (Evommune Inc.) and more on Quantisnow.